sterna biologicals prepares for phase IIB clinical program with GATA-3 antagonist drug candidates SB010 in asthma and SB012 in ulcerative colitis
Marburg, Germany, September 05, 2018
- Key preparatory steps to conduct phase IIb trials initiated, including CMC and regulatory activities in the EU and US
- Devices for SB010 in asthma selected, oral formulation work for SB012 in ulcerative colitis (UC) started
Sterna biologicals GmbH & Co. KG (“sterna”), an innovative clinical-stage immunology company developing novel treatments for chronic inflammatory diseases, today provided an update on its preparations for phase IIb clinical development of its GATA-3 antagonist drug candidates SB010 and SB012.